BuzzSparks.org

Johnson & Johnson Development Corporation


venture capital

Johnson & Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson & Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators,...

Homepage:

HQ

08901 410 George Street

New Brunswick
USA NJ

Phone: (732) 524-3218

Zeev Zehavi Vice President
Marian Nakada Vice President, Venture Investments
Jeanne Bolger Vice President Venture Investing
V. Kadir Kadhiresan VC, Investor
Michael P. Chuisano Vice President, Venture Investments
Jeff Calcagno Principal, Venture Investments
Brad Vale Head of Johnson & Johnson Development Corporation
Asish K. Xavier Vice President, Venture Investments
Bo Liu Principal, Venture Investments
Past
John L. Cassis Founder
Rami Elghandour Principal, Venture Investments
Rami Elghandour Summer Associate, Venture Investments

October, 2013

Johnson & Johnson Development Corporation invested $41.9M in Merus as a Series B round

July, 2013

Johnson & Johnson Development Corporation invested $55M in ReVision Optics as private_equity round

Johnson & Johnson Development Corporation invested $10.6M in ViaCyte as a Series C round

Johnson & Johnson Development Corporation invested $29.6M in CVRx as private_equity round

Johnson & Johnson Development Corporation invested $18M in NeuroPace as partial round

June, 2013

Johnson & Johnson Development Corporation invested unknown amount in Rodin Therapeutics as seed round

Johnson & Johnson Development Corporation invested $14M in Protagonist Therapeutics as a Series B round

April, 2013

Johnson & Johnson Development Corporation invested $18M in Aquinox Pharmaceuticals as a Series C round

March, 2013

Johnson & Johnson Development Corporation invested $48M in Nevro as a Series C round

October, 2012

Johnson & Johnson Development Corporation invested $30M in Genocea Biosciences as a Series C round

June, 2012

Johnson & Johnson Development Corporation invested $40.4M in Astute Medical as a Series C round

Johnson & Johnson Development Corporation invested $23M in PhaseBio Pharmaceuticals as a Series B round

May, 2012

Johnson & Johnson Development Corporation invested $35M in Mitralign as a Series D round

February, 2012

Johnson & Johnson Development Corporation invested $43M in Celladon as unattributed round

January, 2012

Johnson & Johnson Development Corporation invested $12.5M in PowerVision as a Series C round

Johnson & Johnson Development Corporation invested $5M in Pronota as a Series C round

November, 2011

Johnson & Johnson Development Corporation invested $95.9M in Biocartis as a Series C round

July, 2011

Johnson & Johnson Development Corporation invested $58M in Nevro as unattributed round

Johnson & Johnson Development Corporation invested $26.8M in Atlas Genetics as a Series B round

June, 2011

Johnson & Johnson Development Corporation invested $30M in Spinal Modulation as a Series D round

March, 2011

Johnson & Johnson Development Corporation invested $13M in Astute Medical as a Series B round

January, 2011

Johnson & Johnson Development Corporation invested $9M in 23andMe as a Series C round

Johnson & Johnson Development Corporation invested $12.3M in Zeo as a Series C round

Johnson & Johnson Development Corporation invested $35M in Genocea Biosciences as a Series B round

November, 2010

Johnson & Johnson Development Corporation invested $29M in Syntaxin as a Series C round

Johnson & Johnson Development Corporation invested $22M in 23andMe as a Series C round

October, 2010

Johnson & Johnson Development Corporation invested $8.1M in Intio as a Series B round

June, 2010

Johnson & Johnson Development Corporation invested $25M in Aquinox Pharmaceuticals as a Series B round

May, 2010

Johnson & Johnson Development Corporation invested $23M in Breathe Technologies as a Series C round

Johnson & Johnson Development Corporation invested $26.5M in Astute Medical as a Series B round

April, 2010

Johnson & Johnson Development Corporation invested $41.3M in Biocartis as a Series B round

January, 2010

Johnson & Johnson Development Corporation invested $25M in PhaseBio Pharmaceuticals as a Series B round

December, 2009

Johnson & Johnson Development Corporation invested $44.2M in Molecular Partners as a Series B round

November, 2009

Johnson & Johnson Development Corporation invested $27.4M in Spinal Modulation as a Series C round

Johnson & Johnson Development Corporation invested $21.8M in Celladon as a Series C round

October, 2009

Johnson & Johnson Development Corporation invested $20M in Sleep Solutions as a Series F round

Johnson & Johnson Development Corporation invested $40M in Direct Flow Medical as a Series C round

September, 2009

Johnson & Johnson Development Corporation invested $23.7M in Neotract as a Series B round

August, 2009

Johnson & Johnson Development Corporation invested $14.3M in Neurosearch as unattributed round

June, 2009

Johnson & Johnson Development Corporation invested $7.4M in Pronota as a Series B round

Johnson & Johnson Development Corporation invested $21.5M in CoAxia as a Series D round

May, 2009

Johnson & Johnson Development Corporation invested $20.5M in iScience Interventional as a Series F round

February, 2009

Johnson & Johnson Development Corporation invested $5.5M in ImaCor as a Series A round

December, 2008

Johnson & Johnson Development Corporation invested $40M in Catalyst Biosciences as a Series C round

October, 2008

Johnson & Johnson Development Corporation invested $60M in Biolex Therapeutics as a Series D round

August, 2008

Johnson & Johnson Development Corporation invested $27.5M in Brainsgate as unattributed round

Johnson & Johnson Development Corporation invested $9M in Neuron Systems as a Series A round

February, 2008

Johnson & Johnson Development Corporation invested $11M in InSound Medical as a Series E round

October, 2007

Johnson & Johnson Development Corporation invested $32M in Syntaxin as a Series B round

Johnson & Johnson Development Corporation invested $6.6M in PhaseBio Pharmaceuticals as a Series B round

Johnson & Johnson Development Corporation invested $33M in Tengion as a Series C round

August, 2007

Johnson & Johnson Development Corporation invested $15.6M in Molecular Partners as a Series A round

July, 2007

Johnson & Johnson Development Corporation invested $25M in Novocell as a Series C round

May, 2007

Johnson & Johnson Development Corporation invested $30M in Biolex Therapeutics as a Series C round

April, 2007

Johnson & Johnson Development Corporation invested $32M in Metabolex as a Series D round

March, 2007

Johnson & Johnson Development Corporation invested $15.3M in Axial Biotech as a Series B round

June, 2006

Johnson & Johnson Development Corporation invested $50M in Tengion as a Series B round

May, 2006

Johnson & Johnson Development Corporation invested $20M in Novocell as unattributed round

April, 2006

Johnson & Johnson Development Corporation invested $7.8M in Pronota as a Series A round

December, 2005

Johnson & Johnson Development Corporation invested $67M in Light Sciences Oncology as a Series A round

September, 2005

Johnson & Johnson Development Corporation invested $36M in Biolex Therapeutics as a Series B round

August, 2005

Johnson & Johnson Development Corporation invested $39M in Tengion as a Series A round

January, 2005

Johnson & Johnson Development Corporation invested $8M in Biolex Therapeutics as unattributed round